Aurobindo Pharma Director Discharged from Delhi Liquor Policy Case

Aurobindo Pharma Non-Executive Director P. Sarath Chandra Reddy was discharged from the Delhi Liquor Policy case on February 27, 2026, by a CBI court. The court found no material evidence of conspiracy or illegal gratification against Mr. Reddy, who was added as Accused No. 23 on July 29, 2024.

Reader Takeaway: Director Reddy's discharge removes legal overhang; pharma sector regulatory focus remains.

What just happened (today’s filing)

Aurobindo Pharma has issued a clarification following media reports concerning its Non-Executive Director, P. Sarath Chandra Reddy.

The company confirmed that a CBI court discharged Mr. Reddy and 22 other accused from the Delhi Liquor Policy case on February 27, 2026.

This discharge followed the court's finding that there was no material evidence indicating Mr. Reddy's participation in any conspiracy or receiving illegal gratification. Mr. Reddy was originally added as Accused No. 23 in the case on July 29, 2024.

Why this matters

The discharge of Mr. Reddy by the CBI court significantly alleviates a potential legal overhang for Aurobindo Pharma.

It signals a favourable resolution for the director concerning this specific judicial matter, reducing uncertainty for the company and its stakeholders.

The backstory (grounded)

Aurobindo Pharma is a major Indian multinational pharmaceutical company based in Hyderabad, known for manufacturing generic pharmaceuticals and Active Pharmaceutical Ingredients (APIs). [cite:groundedResearch.companySnapshot[0]] Its operations span critical therapeutic areas like cardiovascular and anti-infectives. [cite:groundedResearch.companySnapshot[1]]

The Delhi Liquor Policy case, which led to an FIR by the CBI on August 17, 2022, had seen Mr. P. Sarath Chandra Reddy implicated. [cite:groundedResearch.backstory[1]]

He was officially added as Accused No. 23 on July 29, 2024, and subsequently discharged on February 27, 2026. [cite:groundedResearch.backstory[0, 2]] Mr. Reddy had previously been arrested by the ED in connection with this case and had also turned an approver. [cite:groundedResearch.backstory[4, 5]]

What changes now

• Removal of Director-Specific Legal Risk: The discharge directly removes the judicial proceedings and associated potential penalties against Mr. Reddy in this case.
• Reduced Overhang: The persistent legal uncertainty surrounding Mr. Reddy's involvement is now resolved, potentially improving investor sentiment.
• Focus on Core Business: Management can now concentrate more fully on Aurobindo Pharma's core operations without this specific distraction.
• Governance Clarity: The court's findings of no conspiracy or illegal gratification strengthen the governance perception around key personnel.

Risks to watch

While Mr. Reddy has been discharged, investors will continue to monitor the broader regulatory environment for the pharmaceutical sector in India. Aurobindo Pharma itself has faced past regulatory actions, including warning letters from the USFDA and product recalls due to quality concerns. [cite:groundedResearch.negativeHistory[1, 2, 3]]

The Delhi Liquor Policy case may still have ongoing proceedings for other accused, although Mr. Reddy is no longer a subject.

Peer comparison

Major Indian pharmaceutical players like Dr. Reddy's Laboratories and Sun Pharmaceutical Industries are also subject to regulatory scrutiny typical for the sector. [cite:groundedResearch.peerFacts[0, 1]]

These companies, similar to Aurobindo Pharma, operate in highly regulated markets where adherence to compliance and governance is paramount.

Divi's Laboratories, a key API manufacturer, also faces a landscape demanding stringent quality and regulatory compliance. [cite:groundedResearch.peerFacts[2]]

Context metrics (time-bound)

• P. Sarath Chandra Reddy was named Accused No. 23 on July 29, 2024, within the Delhi Liquor Policy case framework (FIR dated August 17, 2022).
• The CBI court discharged Mr. Reddy and 22 other accused on February 27, 2026, citing a lack of material evidence.

What to track next

• Any updates on the ongoing proceedings of the Delhi Liquor Policy case for the remaining accused.
• Future commentary from Aurobindo Pharma management on director-level governance or regulatory compliance.
• Overall sector performance and any systemic regulatory changes impacting pharmaceutical companies.
• Shareholder voting patterns or board meeting minutes related to director oversight, if publicly available.
• Company's financial performance reports for subsequent quarters, assessing any residual market perception.